Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.55 USD

197.55
4,713,450

+1.18 (0.60%)

Updated Aug 23, 2024 04:00 PM ET

Pre-Market: $197.53 -0.02 (-0.01%) 8:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Key Predictions for Q3 Earnings Reports of ABBV, MRK

The third quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players AbbVie and Merck follow suit.

    Arpita Dutt headshot

    Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod

    Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.

      Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up

      Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.

        Can AbbVie (ABBV) Spring a Surprise this Earnings Season?

        Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.

          Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength

          Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.

            Sweta Killa headshot

            Healthcare ETFs Set to Soar as Q3 Earnings Unfold

            With earnings surprises well in the cards, healthcare ETFs are set to soar.

              Is Gilead (GILD) Poised for a Beat This Earnings Season?

              A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.

                Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics

                AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.

                  Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                  Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                    What's in the Cards for Novartis (NVS) This Earnings Season?

                    Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.

                      Tracey Ryniec headshot

                      Where to Find Value in Healthcare Stocks

                      The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

                        Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

                        Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

                          J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

                          J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

                            The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

                            The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

                              J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use

                              Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.

                                Cancer Space Update: Lung & Breast Cancer Studies in Focus

                                While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

                                  Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock?

                                  Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

                                    Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA

                                    Allergan plc (AGN) announced that the FDA has accepted the new drug application (NDA) for ulipristal acetate, for the treatment of abnormal uterine bleeding in women with uterine fibroids.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

                                      With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

                                        Here's What's Has Happened in the HCV Space Lately

                                        A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.

                                          AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why

                                          AbbVie's (ABBV) shares have gained an impressive 16.7% in the past month supported by a series of positive news for the company in the past few weeks.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation

                                            Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.

                                              Arpita Dutt headshot

                                              Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?

                                              With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.

                                                Merck Drops Two HCV Combination Programs Amid Competition

                                                Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.

                                                  Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China

                                                  Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.